Pancreatic Cancer Research

ResearcherTohoku UniversityActive in the last 2 years

Shuichi Aoki

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4221-0236; OpenAlex author ID A5021491574, A5085068408, A5113035443, A5128839733. Sources: OpenAlex.

Their work

Papers
22 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
78
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 2 papers · 2020: 1 paper · 2021: 3 papers · 2022: 2 papers · 2023: 4 papers · 2024: 1 paper · 2025: 3 papers · 2026: 5 papers

Papers 22

  1. Histological treatment response to neoadjuvant chemotherapy predicts the survival outcomes of patients with resectable pancreatic cancer: validation of the Jap… Co-author DOI 10.1007/s00595-026-03325-w↗
  2. SMAD3 activation in pancreatic stellate cells correlates with PTGDR2 expression and favorable stromal features in pancreatic cancer. Co-author DOI 10.1016/j.pan.2026.03.007↗
  3. Utility of longitudinal changes in CA19-9 for detection of pancreatic ductal adenocarcinoma in patients with benign pancreatic diseases. Co-author DOI 10.1016/j.pan.2026.10.007↗
  4. Randomized phase III trial of gemcitabine plus nab-paclitaxel versus gemcitabine plus S-1 as neoadjuvant chemotherapy for resectable pancreatic cancer in geria… Co-author DOI 10.1093/jjco/hyag055↗
  5. Predictive Factors for Occult Metastases in Clinically M0 Pancreatic Cancer: A Prospective Multicenter Analysis of Staging Laparoscopy. Co-author DOI 10.1245/s10434-026-20728-8↗
  6. A case of FGFR2 fusion-positive pancreatic head tumor with difficult differential diagnosis between cholangiocarcinoma and pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s12328-025-02193-0↗
  7. Preoperative Chemotherapy With Gemcitabine for Pancreatic Cancer Causes Zinc Deficiency. Co-author DOI 10.1097/mpa.0000000000002396↗
  8. Local Recurrence and Survival Outcomes after Portal Vein/Superior Mesenteric Vein Separation without Resection Preceding Neoadjuvant Therapy for Pancreatic Duc… Co-author DOI 10.1097/mpa.0000000000002503↗
  9. Rupture of ectopic varices of the ascending colon occurring after pancreatic cancer surgery: A case report and literature review. Co-author DOI 10.1002/deo2.255↗
  10. Negative prognostic impact of sarcopenia before and after neoadjuvant chemotherapy for pancreatic cancer. Co-author DOI 10.1016/j.pan.2022.11.010↗
  11. Collagen XVII regulates tumor growth in pancreatic cancer through interaction with the tumor microenvironment. Co-author DOI 10.1111/cas.15952↗
  12. CA19-9 With Two-stage Resection Is Useful for Conversion Surgery in PDAC With Synchronous Oligometastases. Co-author DOI 10.21873/anticanres.16724↗
  13. [A Case of an Elderly Patient Who Underwent Conversion Resection for Pancreatic Cancer with Positive Peritoneal Cytology]. First author PMID 36807179↗
  14. What is the impact of zinc deficiency for pancreatectomies in patients with pancreatic ductal adenocarcinoma? Co-author DOI 10.1016/j.pan.2021.12.006↗
  15. Impact of Tumor-Derived DNA Testing in Peritoneal Lavage of Pancreatic Cancer Patients with and Without Occult Intra-Abdominal Metastases. Co-author DOI 10.1245/s10434-021-10997-w↗
  16. Staging laparoscopy is mandatory for the treatment of pancreatic cancer to avoid missing radiologically negative metastases. Co-author DOI 10.1007/s00595-020-02121-4↗
  17. Prognostic value of an inflammation-based nutritional score for patients with initially unresectable pancreatic adenocarcinoma undergoing conversion surgery fo… First author DOI 10.1007/s00595-021-02279-5↗
  18. Preceding Systemic Chemotherapy for Patients with Pancreatic Ductal Adenocarcinoma with Positive Peritoneal Cytology Provides Survival Benefit Compared with Up… Co-author DOI 10.1245/s10434-021-09718-0↗
  19. Prognostic impact of intraoperative peritoneal cytology after neoadjuvant therapy for potentially resectable pancreatic cancer. Co-author DOI 10.1016/j.pan.2020.08.022↗
  20. Sustained Elevation of Postoperative Serum Level of Carbohydrate Antigen 19-9 is High-Risk Stigmata for Primary Hepatic Recurrence in Patients with Curatively … Co-author DOI 10.1007/s00268-018-4814-4↗
  21. Decreased serum carbohydrate antigen 19-9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicente… Co-author DOI 10.1186/s12885-019-5460-4↗
  22. [A case of successful R0 resection after neoadjuvant therapy for locally advanced unresectable pancreatic cancer]. Co-author PMID 24393949↗

Closest collaborators

The 25 strongest of 78 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michiaki Unno · 22 shared papers, 2013–2026 · strength 3.50
  2. Masamichi Mizuma · 19 shared papers, 2013–2026 · strength 2.89
  3. Masahiro Iseki · 12 shared papers, 2021–2026 · strength 2.22
  4. Shimpei Maeda · 10 shared papers, 2020–2026 · strength 1.71
  5. Fuyuhiko Motoi · 12 shared papers, 2013–2026 · strength 1.50
  6. Kei Nakagawa · 11 shared papers, 2013–2025 · strength 1.42
  7. Daisuke Douchi · 7 shared papers, 2023–2026 · strength 1.35
  8. Atsushi Masamune · 5 shared papers, 2024–2026 · strength 1.16
  9. Takanori Morikawa · 9 shared papers, 2013–2023 · strength 1.06
  10. Mitsuhiro Shimura · 5 shared papers, 2023–2026 · strength 1.04
  11. Koetsu Inoue · 4 shared papers, 2023–2026 · strength 0.75
  12. Toru Furukawa · 3 shared papers, 2022–2026 · strength 0.63
  13. Kyohei Ariake · 4 shared papers, 2020–2026 · strength 0.54
  14. Shingo Yoshimachi · 3 shared papers, 2020–2026 · strength 0.53
  15. Koetsu Inoue · 3 shared papers, 2023–2025 · strength 0.50
  16. Takashi Kokumai · 3 shared papers, 2021–2025 · strength 0.49
  17. Kei Kawaguchi · 4 shared papers, 2020–2022 · strength 0.48
  18. Tatsuyuki Takadate · 4 shared papers, 2020–2022 · strength 0.45
  19. Naohiro Hirano · 2 shared papers, 2023–2026 · strength 0.40
  20. Tatsuo Hata · 3 shared papers, 2020–2022 · strength 0.33
  21. Taku Kano · 1 shared paper, 2025 · strength 0.25
  22. Yuichiro Umino · 1 shared paper, 2026 · strength 0.24
  23. Kazuhiro Kikuta · 1 shared paper, 2026 · strength 0.23
  24. Nana Kimura · 1 shared paper, 2026 · strength 0.23
  25. Shin Hamada · 1 shared paper, 2026 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.